<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003954</url>
  </required_header>
  <id_info>
    <org_study_id>1383.00</org_study_id>
    <secondary_id>NCI-2012-00670</secondary_id>
    <secondary_id>P01CA078902</secondary_id>
    <nct_id>NCT00003954</nct_id>
  </id_info>
  <brief_title>Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma</brief_title>
  <official_title>Allogeneic Stem Cell Transplantation For Multiple Myeloma: A Two Step Approach To Reduce Toxicity Involving High Dose Melphalan and Autologous Stem Cell Transplant Followed By PBSC Allografting After Low Dose TBI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Center</source>
  <brief_summary>
    <textblock>
      In this study donor bone marrow transplantation is divided into a two step process to try to&#xD;
      significantly reduce the side effects of the procedure yet still provide patients with&#xD;
      multiple myeloma the benefits of this procedure&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate engraftment of human leukocyte antigen (HLA) identical peripheral blood stem&#xD;
      cell (PBSC) allografts given after conditioning with total-body irradiation (TBI) (200 cGy)&#xD;
      and post-grafting immunosuppression with cyclosporine (CSP)/mycophenolate mofetil (MMF) in&#xD;
      myeloma patients initially cytoreduced with high-dose melphalan.&#xD;
&#xD;
      II. To evaluate non-relapse mortality at day 100 post allografting. III. To evaluate the&#xD;
      efficacy of this allografting strategy in terms of long-term progression free survival (PFS).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      CONDITIONING REGIMEN: Patients receive high-dose melphalan intravenously (IV) over 15-20&#xD;
      minutes on day -2.&#xD;
&#xD;
      TRANSPLANTATION: Patients undergo autologous bone marrow or PBSC transplantation (PBSCT) on&#xD;
      day 0.&#xD;
&#xD;
      NON-MYELOABLATIVE CONDITIONING REGIMEN: Beginning 40-120 days after autologous transplant,&#xD;
      patients undergo TBI on day 0.&#xD;
&#xD;
      TRANSPLANTATION: Patients undergo donor PBSCT on day 0.&#xD;
&#xD;
      IMMUNOSUPPRESSION: Patients receive cyclosporine IV twice daily (BID) on days -1 and 0 and&#xD;
      orally (PO) BID on days 1-80 with taper based on evaluation of disease response and&#xD;
      graft-versus-host disease (GVHD). Patients also receive mycophenolate mofetil PO BID on days&#xD;
      0-27.&#xD;
&#xD;
      POST-TRANSPLANTATION DONOR LYMPHOCYTE INFUSION (DLI): Beginning 4 weeks after&#xD;
      immunosuppression, patients achieving persistent or progressive disease may undergo DLI over&#xD;
      30 minutes every 4 weeks for up to 3 treatments.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1999</start_date>
  <primary_completion_date type="Actual">December 2002</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>From the date of transplant until the time of progression, relapse, death, or the date the patient was last known to be in remission, up to 3 years</time_frame>
    <description>The current study will be regarded as potentially efficacious if the observed 3-year PFS rate among all patients treated exceeds 30%. The Kaplan-Meier (KM) estimate of PFS will be used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decrease in the short-term transplant-related mortality</measure>
    <time_frame>Day 100 after allograft</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Establish stable allogeneic engraftment (mixed or full donor chimerism)</measure>
    <time_frame>At day 56 after allografting</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Estimated by the method of Kaplan and Meier. Confidence intervals will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Summarized using cumulative incidence estimates. Confidence intervals will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Confidence intervals will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to convert mixed to full donor chimerism with DLI</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Confidence intervals will be estimated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Refractory Multiple Myeloma</condition>
  <condition>Stage I Multiple Myeloma</condition>
  <condition>Stage II Multiple Myeloma</condition>
  <condition>Stage III Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN: Patients receive high-dose melphalan IV over 15-20 minutes on day -2.&#xD;
TRANSPLANTATION: Patients undergo autologous bone marrow or PBSCT on day 0.&#xD;
NON-MYELOABLATIVE CONDITIONING REGIMEN: Beginning 40-120 days after autologous transplant, patients undergo TBI on day 0.&#xD;
TRANSPLANTATION: Patients undergo donor PBSCT on day 0.&#xD;
IMMUNOSUPPRESSION: Patients receive cyclosporine IV BID on days -1 and 0 and PO BID on days 1-80 with taper based on evaluation of disease response and GVHD. Patients also receive mycophenolate mofetil PO BID on days 0-27.&#xD;
POST TRANSPLANT DLI: Beginning 4 weeks after immunosuppression, patients achieving persistent or progressive disease may undergo DLI over 30 minutes every 4 weeks for up to 3 treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)</arm_group_label>
    <other_name>Alkeran</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-phenylalanine mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo autologous bone marrow or PBSCT</description>
    <arm_group_label>Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
    <description>Undergo autologous bone marrow or PBSCT</description>
    <arm_group_label>Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)</arm_group_label>
    <other_name>ABMT</other_name>
    <other_name>bone marrow transplantation, autologous</other_name>
    <other_name>transplantation, autologous bone marrow</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Undergo autologous bone marrow or PBSCT</description>
    <arm_group_label>Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>peripheral blood progenitor cell transplantation</other_name>
    <other_name>transplantation, peripheral blood stem cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Undergo donor PBSCT</description>
    <arm_group_label>Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>peripheral blood progenitor cell transplantation</other_name>
    <other_name>transplantation, peripheral blood stem cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)</arm_group_label>
    <other_name>ciclosporin</other_name>
    <other_name>cyclosporin</other_name>
    <other_name>cyclosporin A</other_name>
    <other_name>CYSP</other_name>
    <other_name>Sandimmune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
    <description>Undergo DLI</description>
    <arm_group_label>Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)</arm_group_label>
    <other_name>ALLOLYMPH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet Salmon and Durie criteria for initial diagnosis of multiple myeloma; transplant&#xD;
             will be offered to patients with stage II or III multiple myeloma (MM) at diagnosis or&#xD;
             have received chemotherapy and/or radiation therapy for progressive MM after initial&#xD;
             diagnosis of stage I disease&#xD;
&#xD;
          -  The patient must have the capacity to give informed consent&#xD;
&#xD;
          -  Have received at least 4 cycles of conventional dose chemotherapy for MM&#xD;
&#xD;
          -  DONOR: HLA genotypically identical sibling&#xD;
&#xD;
          -  DONOR: Donor must consent to filgrastim (G-CSF) administration and leukapheresis for&#xD;
             both peripheral blood stem cell (PBSC) allograft and subsequent DLI&#xD;
&#xD;
          -  DONOR: Donor must have adequate veins for leukapheresis or agree to placement of&#xD;
             central venous catheter (femoral, subclavian)&#xD;
&#xD;
          -  DONOR: Age &lt; 75, older donors may be considered after consultation by Psychological&#xD;
             Consultation Center (PCC)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Karnofsky score less than 60, unless due solely to myeloma&#xD;
&#xD;
          -  Left ventricular ejection fraction less than 40%&#xD;
&#xD;
          -  Bilirubin greater than 2 X the upper limit of normal&#xD;
&#xD;
          -  Serum glutamic pyruvic transaminase (SGPT) and serum glutamic oxaloacetic transaminase&#xD;
             (SGOT) &gt; 2 X the upper limit of normal&#xD;
&#xD;
          -  Diffusion lung capacity of carbon monoxide (DLCO) &lt; 50% (corrected) or receiving&#xD;
             continuous supplemental oxygen&#xD;
&#xD;
          -  Patients with poorly controlled hypertension&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Seropositive for the human immunodeficiency virus&#xD;
&#xD;
          -  Fertile men or women unwilling to use contraceptive techniques during and for 12&#xD;
             months following treatment&#xD;
&#xD;
          -  Creatinine clearance &lt; 40 cc/min at the time of initial autografting evaluation&#xD;
&#xD;
          -  Prior autograft (can be treated on alternative protocol)&#xD;
&#xD;
          -  DONOR: Identical twin&#xD;
&#xD;
          -  DONOR: Age less than 12 years&#xD;
&#xD;
          -  DONOR: Pregnancy&#xD;
&#xD;
          -  DONOR: Infection with human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  DONOR: Inability to achieve adequate venous access&#xD;
&#xD;
          -  DONOR: Known allergy to G-CSF&#xD;
&#xD;
          -  DONOR: Current serious systemic illness&#xD;
&#xD;
          -  DONOR: Failure to meet Fred Hutchinson Cancer Research Center (FHCRC) criteria for&#xD;
             stem cell donation as described in the standard practice guidelines of the institution&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Maloney</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 14, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2004</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

